查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733379

全球儿科疫苗开发市场规模（按类型、技术、应用、区域范围和预测）

Global Pediatric Vaccines Development Market Size By Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Subunit), By Application (Infectious Disease, Cancer, Allergy), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

儿童疫苗开发市场规模及预测

2024 年儿科疫苗开发市场规模价值为 314 亿美元，预计到 2032 年将达到 686 亿美元，在 2026-2032 年预测期内的复合年增长率为 10.3%。

千禧世代中，科技主导的个人成长平台的日益普及也有望对预测期内的市场成长产生正面影响。预计预测期内，人们对疫苗和免疫意识的提高将推动全球儿科疫苗开发市场的成长。全球儿科疫苗开发市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

推动全球儿科疫苗开发市场的因素

儿科疫苗开发市场的市场驱动力受到多种因素的影响。这些包括：

增加知识并专注于预防性医疗保健：随着父母和医疗保健提供者对免疫接种在预防儿童疾病方面的价值的认识不断提高，对儿科疫苗的需求也随之增加。

政府措施和免疫计画：政府主导的免疫计画和倡议正在扩大免疫接种的覆盖面，尤其是在开发中国家。

新型佐剂、递送系统和重组 DNA 技术的开发是疫苗研究领域的技术进步之一，这些进步正在加速儿科疫苗的开发并提高其有效性和安全性。

感染疾病增多：儿童感染疾病持续爆发，包括麻疹、流感、肺炎和脑膜炎，推动了儿童疫苗的需求。

增加疫苗研发资金：政府、非营利组织和製药公司对儿童疫苗研发的投入不断增加，正在刺激创新并有助于扩大市场。

提高疫苗接种覆盖率：全球对儿科免疫接种的需求受到提高疫苗接种覆盖率的措施的推动，例如补种疫苗接种计划和常规免疫接种计划。

新兴感染疾病威胁：伊波拉和兹卡病毒等新兴感染疾病的威胁日益增加，凸显了继续努力生产疫苗以应对不断演变的公共卫生问题的重要性。

专注于根除和消除疾病：全球为消除或减少麻疹和脊髓灰质炎等可透过疫苗预防的疾病所做的努力推动了儿童免疫接种的需求，这推动了市场的成长。

国际卫生组织、小儿科和其他医疗保健专业人员的倡导工作支持将疫苗接种作为公共卫生干预措施。这导致儿童疫苗的接受度和接种率有所提高。

技术和製造进步：基于细胞培养和重组疫苗製造平台以及其他疫苗製造技术的开发，使疫苗更具可扩展性、效率和成本效益，有助于扩大市场。

限制全球儿科疫苗开发市场的因素

多种因素可能对儿科疫苗开发市场造成市场限制和挑战。这些包括：

严格的监管要求：儿科疫苗漫长的核准流程往往会延迟新产品的开发和上市。

开发成本高：由于开发儿科疫苗的成本高昂，包括研究和临床测试，规模较小的生物技术公司和学术机构可能难以在市场上创新和竞争。

罕见疾病的市场潜力有限：开发针对罕见儿童疾病的疫苗成本很高，并且没有可观的投资收益来涵盖开发成本。

错误讯息和疫苗不信任：错误讯息和疫苗不信任会阻碍疫苗宣传活动，减少对儿童疫苗接种者的需求并阻碍市场扩张。

低温运输需求：维护疫苗分发和储存的低温运输在物流上具有挑战性且成本高昂，尤其是在农村和资源贫乏的地区。这可能会影响疫苗接种的取得和接种。

智慧财产权和专利问题：对疫苗接种技术和发展的担忧可能导致法律纠纷和市场进入延迟，从而抑制创新和竞争。

疫苗供应链中断，包括製造问题、原材料短缺和分销困难，可能会影响市场稳定并导致供不应求。

全球健康公平挑战：高所得和低收入国家在获得儿童疫苗方面存在的不平等可能会限制市场扩张并阻碍全民免疫的努力，从而加剧全球健康差距。

安全问题和不利事件：有关儿童免疫接种的安全问题和不利事件的报告可能会破坏公众对免疫接种计划的信任和信心。这可能会导致疫苗接种率和市场需求下降。

现有疫苗的竞争：在拥挤的疫苗市场中，来自安全性和有效性已得到证实的儿科疫苗的竞争会使新疫苗难以获得市场占有率。

目录

第一章全球儿科疫苗开发市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球儿科疫苗发展市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球儿科疫苗开发市场（按类型）

  • 概述
  • 单一值
  • 多效价

6. 全球儿童疫苗开发市场（依技术）

  • 概述
  • 生的
  • 失活
  • 次单元
  • 类毒素
  • 结合物
  • 其他的

7. 全球儿童疫苗开发市场（按应用）

  • 概述
  • 感染疾病
  • 癌症
  • 过敏

8. 全球儿科疫苗开发市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球儿科疫苗开发市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • GlaxoSmithKline plc
  • Merck Sharp & Dohme Corp.
  • SANOFI
  • AstraZeneca
  • Pfizer, Inc.
  • Zydus Cadila
  • Indian Immunologicals Limited
  • Serum Institute of India Pvt. Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea BIoTec

第十一章 附录

  • 相关调查
简介目录
Product Code: 65663

Pediatric Vaccines Development Market Size And Forecast

Pediatric Vaccines Development Market size was valued at USD 31.4 Billion in 2024 and is projected to reach USD 68.6 Billion by 2032, growing at a CAGR of 10.3% from 2026 to 2032.

The rising popularity of technology-driven platforms for self-growth amongst millennials is also expected to positively impact market growth during the forecast period. Increasing awareness regarding vaccines and immunization among the populace is expected to boost the growth of the global Pediatric Vaccines Development Market over the forecast period. The Global Pediatric Vaccines Development Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Pediatric Vaccines Development Market Drivers

The market drivers for the Pediatric Vaccines Development Market can be influenced by various factors. These may include:

Growing Knowledge and Focus on Preventive Healthcare: The need for paediatric vaccines is being driven by parents' and healthcare professionals' growing understanding of the value of immunisation in preventing childhood illnesses.

Government Initiatives and Immunisation Programmes: Growing access to vaccinations, especially in developing nations, is being facilitated by government-led immunisation programmes and initiatives.

The development of new adjuvants, delivery systems, and recombinant DNA techniques is among the technological advancements in vaccine research that are speeding up the development of paediatric vaccines and enhancing their efficacy and safety profiles.

Growing Incidence of Infectious Diseases: The demand for paediatric vaccination is being driven by the persistent incidence of infectious diseases in children, including measles, influenza, pneumonia, and meningitis.

More Funding for Vaccine Research and Development: Growing investments in paediatric vaccine research and development from governments, nonprofits, and pharmaceutical corporations are stimulating innovation and propelling market expansion.

Increasing Vaccination Coverage: Worldwide demand for paediatric vaccinations is being driven by initiatives to raise vaccination coverage rates, such as catch-up vaccination programmes and regular immunisation schedules.

Threats from Emerging Infectious Diseases: The rise in threats from emerging infectious diseases, such the Ebola and Zika viruses, emphasises the significance of ongoing attempts to produce vaccines to address changing public health issues.

Emphasis on Disease Eradication and Elimination: Demand for paediatric vaccinations is being driven by global measures to eradicate or reduce vaccine-preventable illnesses like measles and polio, which is bolstering the growth of the market.

The promotion of vaccination as a public health intervention is being aided by the advocacy efforts of international health organisations, paediatricians, and other healthcare professionals. This has led to a rise in the acceptance and uptake of paediatric vaccines.

Technological and Manufacturing Advancements: The development of cell culture-based and recombinant vaccine production platforms, among other vaccine manufacturing technologies, is increasing the scalability, efficiency, and cost-effectiveness of vaccines and propelling their market expansion.

Global Pediatric Vaccines Development Market Restraints

Several factors can act as restraints or challenges for the Pediatric Vaccines Development Market. These may include:

Strict Regulatory Requirements: The lengthy and strict regulatory approval procedures for paediatric vaccines frequently cause delays in the development of new products and the launch of new products.

High Development expenses: Smaller biotechnology businesses and academic institutions may find it difficult to innovate and remain competitive in the market due to the high expenses involved in developing paediatric vaccines, which include research and clinical trials.

Limited Market Potential for Rare disorders: It can be expensive to create vaccines for rare paediatric disorders when there may not be a significant return on investment to cover development expenses.

Misinformation and Vaccine reluctance: Misinformation and vaccine mistrust can cause vaccine reluctance, which can obstruct immunisation campaigns, lower demand for paediatric vaccinations, and hamper market expansion.

Cold Chain requirements: It can be logistically difficult and expensive to maintain the cold chain for vaccine distribution and storage, particularly in rural and resource-constrained places. This can have an influence on vaccination accessibility and adoption.

Intellectual property rights and patent issues: Concerns over vaccination technology and development can give rise to legal battles and market entry delays, which can impede innovation and competition.

Disruptions in the vaccine supply chain, such as problems with manufacturing, shortages of raw materials, or difficulties with distribution, can affect the stability of the market and result in supply shortages.

Global Health Equity Challenges: Inequalities in high- and low-income nations' access to paediatric vaccines might worsen global health disparities by restricting market expansion and impeding attempts to attain universal immunisation coverage.

Safety worries and Adverse Events: The public's trust and confidence in vaccination programmes can be damaged by safety worries and reports of adverse events linked to paediatric vaccinations. This can result in a decline in vaccine uptake and market demand.

Competition from Established Vaccines: In crowded vaccine markets, it can be difficult for novel vaccines to obtain market share due to competition with established paediatric vaccines with well-known safety and effectiveness characteristics.

Global Pediatric Vaccines Development Market Segmentation Analysis

The Global Pediatric Vaccines Development Market is Segmented Based on Type, Technology, Application, And Geography.

Pediatric Vaccines Development Market, By Type

  • Monovalent
  • Multivalent

Based on Type, The market is bifurcated into Monovalent, Multivalent. The Monovalent segment is expected to inflate the market growth owing to their safety and stability and their ability to develop a rapid immune response.

Pediatric Vaccines Development Market, By Technology

  • Live Attenuated
  • Inactivated
  • Subunit
  • Toxoid
  • Conjugate
  • Others

Based on Technology, The market is bifurcated into Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Others. The Conjugate segment is expected to inflate the market growth. This can be attributed to an increase in the prevalence of pneumococcal and meningococcal infections and a rise in awareness regarding the prevention of diseases.

Pediatric Vaccines Development Market, By Application

  • Infectious Disease
  • Cancer
  • Allergy

Based on Application, The market is bifurcated into Infectious Disease, Cancer, and Allergy. Infectious Disease is anticipated to become the fastest-growing market in the forecast duration due to growing global awareness about immunization against a number of infectious diseases that cause mortality and morbidity.

Pediatric Vaccines Development Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, The Global Pediatric Vaccines Development Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is expected to hold the largest market share in the forecast period. Some of the key factors that can be attributed to its dominance are an increase in R&D investments by numerous companies and a rise in government support for immunization and the development of pediatric vaccines. In addition, the presence of advanced healthcare infrastructure and facilities for immunization supports the growth of this segment.

Key Players

The "Global Pediatric Vaccines Development Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, Merck Sharp & Dohme Corp., SANOFI, AstraZeneca, Pfizer, Inc., Zydus Cadila, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Mitsubishi Tanabe Pharma Corporation, and Panacea Biotec. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Monovalent
  • 5.3 Multivalent

6 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY TECHNOLOGY

  • 6.1 Overview
  • 6.2 Live Attenuated
  • 6.3 Inactivated
  • 6.4 Subunit
  • 6.5 Toxoid
  • 6.6 Conjugate
  • 6.7 Others

7 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Infectious Disease
  • 7.3 Cancer
  • 7.4 Allergy

8 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 GlaxoSmithKline plc
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Merck Sharp & Dohme Corp.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 SANOFI
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 AstraZeneca
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Pfizer, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Zydus Cadila
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Indian Immunologicals Limited
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Serum Institute of India Pvt. Ltd.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Mitsubishi Tanabe Pharma Corporation
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Panacea Biotec
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research